Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMHZ3DE)

Drug Name
AZD6765 Drug Info
Synonyms
Lanicemine; 153322-05-5; AZD6765; UNII-9TMU325RK3; AR-R15896AR; ARL 15896; 9TMU325RK3; AZD-6765; (1S)-1-phenyl-2-(pyridin-2-yl)ethan-1-amine; Lanicemine [INN]; FPL 15896; AR-R 15896; GTPL7681; CHEMBL467084; SCHEMBL1422817; ZINC6163; AR-R-15896AR; MolPort-030-004-688; AKOS026744074; DB11889; AJ-08269; (1S)-1-phenyl-2-pyridin-2-ylethanamine; (+)-2-((S)-beta-Aminophenethyl)pyridine; ( )-2-(S)-beta-Aminophenethyl-pyridine.; Z2286637868
Cross-matching ID
PubChem CID
9794203
ChEBI ID
CHEMBL467084
CAS Number
CAS 153322-05-5
TTD Drug ID
D0OK9X

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Aldosterone-regulated sodium reabsorption 1.87 8.23e-2 34/37 (91.89%) SFN;PDPK1;ATP1A1;...
Autoimmune thyroid disease 1.81 7.72e-2 46/53 (86.79%) HLA-DQA1;GZMB;HLA-DRA;...
Graft-versus-host disease 1.76 9.26e-2 32/42 (76.19%) HLA-DQA1;GZMB;HLA-DRA;...
Allograft rejection 1.76 6.95e-2 32/38 (84.21%) HLA-DQA1;GZMB;HLA-DRA;...
Histidine metabolism 1.62 2.22e-1 16/22 (72.73%) HNMT;MAOB;ALDH2;...
Inflammatory bowel disease 1.57 2.98e-1 58/65 (89.23%) HLA-DQA1;TLR5;STAT3;...
Antigen processing and presentation 1.56 2.82e-1 60/78 (76.92%) HLA-DQA1;IFI30;CD4;...
Complement and coagulation cascades 1.53 2.95e-1 76/85 (89.41%) SERPINA1;F5;PLAT;...
Type I diabetes mellitus 1.52 2.80e-1 38/43 (88.37%) HLA-DQA1;GZMB;HLA-DRA;...
PD-L1 expression and PD-1 checkpoint pathway in cancer 1.51 2.77e-1 79/89 (88.76%) RASGRP1;MYD88;CD4;...
Protein export 1.50 2.79e-1 17/23 (73.91%) SRPRA;SRP9;SEC63;...
Staphylococcus aureus infection 1.47 3.42e-1 72/95 (75.79%) KRT19;HLA-DQA1;C1R;...
Systemic lupus erythematosus 1.47 3.18e-1 45/135 (33.33%) HLA-DQA1;C1R;C1S;...
Th1 and Th2 cell differentiation 1.47 3.00e-1 80/92 (86.96%) HLA-DQA1;CD4;NOTCH2;...
Central carbon metabolism in cancer 1.45 3.18e-1 67/70 (95.71%) FGFR3;PGAM1;ERBB2;...
Caffeine metabolism 1.44 3.34e-1 5/6 (83.33%) CYP2A6;NAT1;CYP1A2;...
Th17 cell differentiation 1.40 3.91e-1 95/107 (88.79%) HLA-DQA1;IL6ST;CD4;...
Thyroid cancer 1.39 4.16e-1 36/37 (97.3%) CDH1;DDB2;CTNNB1;...
Fc epsilon RI signaling pathway 1.38 4.16e-1 57/68 (83.82%) LYN;MAPK13;PDPK1;...
Bladder cancer 1.37 4.27e-1 40/41 (97.56%) FGFR3;CDH1;VEGFA;...
Melanogenesis 1.36 4.29e-1 74/101 (73.27%) EDN1;WNT5A;DVL3;...
Intestinal immune network for IgA production 1.35 4.41e-1 38/48 (79.17%) HLA-DQA1;HLA-DRA;HLA-DRB1;...
Viral myocarditis 1.35 4.31e-1 53/60 (88.33%) HLA-DQA1;CYCS;HLA-DRA;...
Hematopoietic cell lineage 1.33 4.54e-1 90/99 (90.91%) HLA-DQA1;CD14;CD1E;...
Salivary secretion 1.33 4.65e-1 76/93 (81.72%) CST3;ITPR3;ADRB2;...
Leishmaniasis 1.33 4.49e-1 67/77 (87.01%) HLA-DQA1;MYD88;MAPK13;...
Rheumatoid arthritis 1.32 4.70e-1 78/93 (83.87%) HLA-DQA1;CCL20;VEGFA;...
Pathogenic Escherichia coli infection 1.30 4.69e-1 152/197 (77.16%) TJP1;MYD88;MYO6;...
T cell receptor signaling pathway 1.29 4.73e-1 93/104 (89.42%) RASGRP1;CD4;MAPK13;...
NF-kappa B signaling pathway 1.29 4.63e-1 90/104 (86.54%) CCL19;CD14;LYN;...
Hepatocellular carcinoma -1.16 6.32e-1 135/168 (80.36%) TGFB1;TGFBR2;AKT1;...
Malaria -1.16 6.35e-1 44/50 (88%) TGFB1;VCAM1;SDC1;...
Steroid hormone biosynthesis -1.16 6.46e-1 43/61 (70.49%) UGT2B4;CYP11B2;CYP3A5;...
Colorectal cancer -1.16 6.49e-1 84/86 (97.67%) TGFB1;TGFBR2;AKT1;...
Glycine, serine and threonine metabolism -1.20 6.50e-1 31/40 (77.5%) GATM;CTH;BPGM;...
Porphyrin and chlorophyll metabolism -1.21 6.49e-1 23/43 (53.49%) UGT2B17;CPOX;PPOX;...
Neutrophil extracellular trap formation -1.22 6.27e-1 101/189 (53.44%) RAC2;CR1;SLC25A6;...
TGF-beta signaling pathway -1.23 6.15e-1 81/94 (86.17%) TGFB2;NBL1;BMPR2;...
Huntington disease -1.23 6.22e-1 233/306 (76.14%) SDHD;SLC25A5;PSMB3;...
Human papillomavirus infection -1.24 6.19e-1 284/331 (85.8%) ITGB5;PPP2R3A;AKT1;...
PPAR signaling pathway -1.24 6.34e-1 66/74 (89.19%) ACSL4;FABP6;FADS2;...
NOD-like receptor signaling pathway -1.30 6.18e-1 145/181 (80.11%) FADD;IFNAR1;RHOA;...
Glycosaminoglycan biosynthesis -1.31 6.15e-1 40/58 (68.97%) EXTL2;NDST1;HS3ST1;...
Prion disease -1.31 6.43e-1 209/273 (76.56%) SDHD;SLC25A5;PSMB3;...
Epithelial cell signaling in Helicobacter pylori infect... -1.33 5.81e-1 62/70 (88.57%) CXCL3;ATP6V0D1;MAPK9;...
Fatty acid biosynthesis -1.33 6.16e-1 16/18 (88.89%) ACSL1;CBR4;HSD17B8;...
Lysosome -1.33 6.51e-1 115/128 (89.84%) GGA3;CTSH;CLN3;...
Mannose type O-glycan biosynthesis -1.38 5.28e-1 14/23 (60.87%) FUT9;RXYLT1;B4GALT3
Basal transcription factors -1.39 5.34e-1 37/45 (82.22%) TAF6;GTF2H1;TAF2;...
Small cell lung cancer -1.40 5.42e-1 90/92 (97.83%) LAMB3;COL4A2;COL4A1;...
Pentose and glucuronate interconversions -1.41 5.73e-1 17/34 (50%) UGT2B4;UGDH;DCXR;...
Glycosphingolipid biosynthesis -1.44 5.22e-1 37/57 (64.91%) ST3GAL4;HEXA;GLB1;...
Cysteine and methionine metabolism -1.46 4.95e-1 43/50 (86%) DNMT3B;BHMT2;AHCY;...
Ferroptosis -1.50 4.22e-1 36/41 (87.8%) ACSL1;SLC7A11;ATG7;...
Glutathione metabolism -1.51 4.46e-1 43/57 (75.44%) PGD;G6PD;GSTA1;...
Vibrio cholerae infection -1.59 2.48e-1 44/50 (88%) ACTB;SLC12A2;CFTR;...
ECM-receptor interaction -1.61 2.57e-1 80/88 (90.91%) LAMB3;COL4A2;COL4A1;...
Oxidative phosphorylation -1.63 3.16e-1 93/133 (69.92%) ATP5F1B;ATP6AP1;SDHD;...
Collecting duct acid secretion -1.63 4.60e-1 22/27 (81.48%) ATP6V0A2;SLC4A1;ATP6V0D1;...
Synaptic vesicle cycle -1.66 6.30e-1 63/78 (80.77%) AP2A2;AP2M1;SLC6A9;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SK-ES-1 CVCL_0627 Homo sapiens 1.11uM - 10uM 24H
Brain
Glioma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GI-1 CVCL_1230 Homo sapiens 1.11uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MDA-MB-468 CVCL_0419 Homo sapiens 1.11uM - 10uM 24H
Breast ductal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
T-47D CVCL_0553 Homo sapiens 1.11uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SNU-407 CVCL_5004 Homo sapiens 1.11uM - 10uM 24H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 1.11uM - 10uM 24H
HEC-1-A CVCL_0293 Homo sapiens 1.11uM - 10uM 24H
HEC-251 CVCL_2928 Homo sapiens 1.11uM - 10uM 24H
HEC-265 CVCL_2929 Homo sapiens 1.11uM - 10uM 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CJM CVCL_U797 Homo sapiens 1.11uM - 10uM 24H
Liver
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHH-5 CVCL_1320 Homo sapiens 1.11uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1573 CVCL_1483 Homo sapiens 1.11uM - 10uM 24H
NCI-H838 CVCL_1594 Homo sapiens 1.11uM - 10uM 24H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BEN CVCL_1081 Homo sapiens 1.11uM - 10uM 24H
HCC95 CVCL_1276 Homo sapiens 1.11uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H2110 CVCL_1529 Homo sapiens 1.11uM - 10uM 24H
Muscle
Rhabdomyosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-204 CVCL_0134 Homo sapiens 1.11uM - 10uM 24H
Ovary
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OVTOKO CVCL_3114 Homo sapiens 1.11uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
22Rv1 CVCL_1045 Homo sapiens 1.11uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
IGR-37 CVCL_1303 Homo sapiens 1.11uM - 10uM 24H
Mel-HO CVCL_1402 Homo sapiens 1.11uM - 10uM 24H
SH-4 CVCL_1692 Homo sapiens 1.11uM - 10uM 24H
Urinary bladder
Bladder carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BC-3C CVCL_1079 Homo sapiens 1.11uM - 10uM 24H
Bladder transitional cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CAL-29 CVCL_1109 Homo sapiens 1.11uM - 10uM 24H